reports
MediWound Reports New Clinical Data Demonstrating NexoBrid®’s Effectiv...
MediWound Reports New Clinical Data Demonstrating NexoBrid®’s Effectiveness in Preventing Traumatic Tattoos After Abrasion and Blast Injuries MediWound Reports New Clinical Data Demonstrating NexoBrid®’s Effectiveness in Preventing Traumatic Tattoos After Abrasion and Blast Injuries Prospective clinical data show NexoBrid® removes embedded particles in friction and blast wounds, reducing pigmented wound surface by >90% Traumatic tattoos form when dirt, metal, or explosive residue becomes permanently embedded in the skin; findings support further evaluation in acute trauma settings YA...
MediWound Reports Third Quarter 2025 Financial Results and Provides Co...
MediWound Reports Third Quarter 2025 Financial Results and Provides Corporate Update Ongoing Enrollment Continues in VALUE Phase III Trial of EscharEx® in Venous Leg Ulcers Commissioning Completed for Expanded NexoBrid® Facility; Full Operational Capacity Expected by Year-End 2025 Balance Sheet Strengthened with $30 Million Equity Financing Third Quarter 2025 Revenue of $5.4 Million, Up 23% Year-over-Year Conference Call Today, November 20, 2025, at 8:30 a.m. Eastern Time YAVNE, Israel, Nov. 20, 2025 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generati...
MediWound to Report Third Quarter 2025 Financial Results
MediWound to Report Third Quarter 2025 Financial Results MediWound to Report Third Quarter 2025 Financial Results Conference call and webcast scheduled for Thursday, November 20 at 8:30 a.m. Eastern Time YAVNE, Israel, November 5, 2025 -- MediWound Ltd. (Nasdaq: MDWD) (the “Company”), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that it will release its financial results for the third quarter ended September 30, 2025 on Thursday, November 20, 2025. Following the release, the Company’s management will host a conference call and live webcas...
MediWound Successfully Completes Commissioning of Expanded GMP Manufac...
MediWound Successfully Completes Commissioning of Expanded GMP Manufacturing Facility for NexoBrid® MediWound Successfully Completes Commissioning of Expanded GMP Manufacturing Facility for NexoBrid® Newly commissioned facility marks a significant development toward a sixfold production capacity increase ahead of full operational readiness by year-end 2025 YAVNE, Israel, November 3, 2025 – MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced the successful completion of the commissioning process for its expanded GMP ma...
MediWound Announces $30 Million Registered Direct Offering of Ordinary...
MediWound Announces $30 Million Registered Direct Offering of Ordinary Shares MediWound Announces $30 Million Registered Direct Offering of Ordinary Shares YAVNE, Israel, September 29, 2025 -- MediWound Ltd. (Nasdaq: MDWD) (the “Company”), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that it has entered into a definitive securities purchase agreement led by a prominent U.S.-based mutual fund and other healthcare-focused investors for the sale and purchase of 1,734,105 ordinary shares of the Company, par value NIS 0.07 per share, at a purchase...
MediWound Expands Global Reach with Marketing Approval of NexoBrid® in...
MediWound Expands Global Reach with Marketing Approval of NexoBrid® in Australia MediWound Expands Global Reach with Marketing Approval of NexoBrid® in Australia TGA Approves NexoBrid® for Adults and Children; Manufacturing Readiness Positions MediWound for 2025 Launch and Asia-Pacific Expansion YAVNE, Israel, September 25, 2025 -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that Australia’s Therapeutic Goods Administration (TGA) has granted marketing authorization for NexoBrid®, the Company’s innovative e...
MediWound’s NexoBrid® to be Highlighted in 36 Scientific Presentations...
MediWound’s NexoBrid® to be Highlighted in 36 Scientific Presentations at the 21st European Burns Association Congress MediWound’s NexoBrid® to be Highlighted in 36 Scientific Presentations at the 21st European Burns Association Congress YAVNE, Israel, September 2, 2025 -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced its participation at the 21st European Burns Association (EBA) Congress, taking place September 3-6, 2025, in Berlin, Germany. NexoBrid®, the company’s enzymatic burn debridement therapy, will be f...
MediWound Ltd: 1 director
A director at MediWound Ltd bought 11,200 shares at 17.740USD and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly...
MediWound to Present at the H.C. Wainwright 27th Annual Global Investm...
MediWound to Present at the H.C. Wainwright 27th Annual Global Investment Conference YAVNE, Israel, August 20, 2025 -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that Ofer Gonen, Chief Executive Officer, will participate in a fireside chat, hosted by Swayampakula Ramakanth, Managing Director, Senior Equity Research Analyst, on Monday, September 8, 2025 at 4:30p.m. ET at the H.C. Wainwright 27th Annual Global Investment Conference. A live webcast of the event will be accessible both and on MediWound’s website,...
MediWound Reports Second Quarter 2025 Financial Results and Provides C...
MediWound Reports Second Quarter 2025 Financial Results and Provides Corporate Update VALUE Phase III Trial of EscharEx® in Venous Leg Ulcers Continues to Enroll Patients NexoBrid® Manufacturing Expansion on Track; Full Operational Capacity Expected by Year-End 2025 Additional Strategic Research Collaborations Established with Essity and Convatec Second Quarter 2025 Revenue of $5.7 Million, Up 43% from Prior Quarter Conference Call Today, August 14, 2025, at 8:30am Eastern Time YAVNE, Israel, Aug. 14, 2025 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-ge...
MediWound Announces New EscharEx® Phase II Data Demonstrating Strong L...
MediWound Announces New EscharEx® Phase II Data Demonstrating Strong Link Between Wound Bed Preparation and Wound Closure in Venous Leg Ulcers MediWound Announces New EscharEx® Phase II Data Demonstrating Strong Link Between Wound Bed Preparation and Wound Closure in Venous Leg Ulcers Post hoc analysis published in Advances in Wound Care, provides clinical evidence supporting wound bed preparation as a critical step in the healing process YAVNE, Israel, August 13, 2025 (GLOBE NEWSWIRE) – MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue re...
MediWound to Report Second Quarter 2025 Financial Results
MediWound to Report Second Quarter 2025 Financial Results MediWound to Report Second Quarter 2025 Financial Results Conference call and webcast scheduled for Thursday, August 14 at 8:30 a.m. Eastern Time YAVNE, Israel, August 4, 2025 -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that it will release its financial results for the second quarter ended June 30, 2025 on Thursday, August 14, 2025. Following the release, MediWound’s management will host a conference call and live webcast at 8:30 a.m. Eastern Time...
MediWound Reports First Quarter 2025 Financial Results and Provides Co...
MediWound Reports First Quarter 2025 Financial Results and Provides Corporate Update VALUE Phase III trial of EscharEx® in venous leg ulcers advancing as planned NexoBrid® manufacturing expansion on track; full operational capacity expected by year-end 2025 First quarter revenue of $4 million; full-year 2025 revenue guidance reaffirmed at $24 million Conference call today, May 21 at 8:30am Eastern Time YAVNE, Israel, May 21, 2025 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced financial res...
MediWound Announces Publication of Phase II EscharEx® Data Demonstrati...
MediWound Announces Publication of Phase II EscharEx® Data Demonstrating Superiority Over Collagenase in Venous Leg Ulcers Post hoc analysis published in the peer-reviewed journal Wounds highlights EscharEx®’s superior clinical performance and comparable safety profile to SANTYL® YAVNE, Israel, May 13, 2025 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced the publication of a peer-reviewed post hoc analysis in Wounds. The analysis is based on data from the Company’s Phase II ChronEx clinical t...
MediWound to Report First Quarter 2025 Financial Results
MediWound to Report First Quarter 2025 Financial Results Conference call and webcast scheduled for Wednesday, May 21, 2025, at 8:30 a.m. Eastern Time YAVNE, Israel, May 05, 2025 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that it will report financial results for the first quarter ended March 31, 2025 on Wednesday, May 21, 2025. Following the release, MediWound’s management will host a conference call and live webcast at 8:30 a.m. Eastern Time to discuss these financial resul...
MediWound to Present New EscharEx® Data at Leading Wound Care Conferen...
MediWound to Present New EscharEx® Data at Leading Wound Care Conferences Presentations at WHS and SAWC to highlight EscharEx’s mechanism of action, preclinical advantages over SANTYL®, and new data in treating VLUs and DFUs Findings reinforce the ongoing Phase III study in VLUs and support the planned DFU trial strategy YAVNE, Israel, April 28, 2025 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that it will present 10 scientific abstracts—including both oral and poster pres...
MediWound Reports Fourth Quarter and Full Year 2024 Financial Results ...
MediWound Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update Initiated VALUE, a global Phase III pivotal trial of EscharEx® for venous leg ulcers Expanded strategic research collaborations with industry leaders, now including Kerecis $20 million in revenue for 2024; $24 million projected for 2025; $44 million in cash as of Year-End 2024 Conference call today, March 19 at 8:30am Eastern Time YAVNE, Israel, March 19, 2025 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, t...
MediWound to Report Fourth Quarter and Full Year 2024 Financial Result...
MediWound to Report Fourth Quarter and Full Year 2024 Financial Results Conference call and webcast scheduled for Wednesday, March 19th at 8:30 a.m. Eastern Time YAVNE, Israel, March 03, 2025 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that it will release its financial results for the fourth quarter and full year ended December 31, 2024 on Wednesday, March 19, 2025. Following the release, MediWound’s management will host a conference call and live webcast at 8:30 a.m. Eastern Time to ...
MediWound Announces Phase III CIDS Publication on NexoBrid® for Pediat...
MediWound Announces Phase III CIDS Publication on NexoBrid® for Pediatric Burn Care Findings in Burns Journal confirm NexoBrid’s superiority over standard of care in pediatric patients with deep thermal burnsNexoBrid is approved for pediatric use in the U.S., E.U. and Japan YAVNE, Israel, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced the publication of its Phase III Children Innovative Debridement Study (CIDS) in , the peer-reviewed Journal of the International Society for Burn Injuries...
MediWound to Present at the 45th Annual TD Cowen Health Care Conferenc...
MediWound to Present at the 45th Annual TD Cowen Health Care Conference YAVNE, Israel, Feb. 24, 2025 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that Chief Executive Officer Ofer Gonen will present a corporate overview at the upcoming 45th Annual TD Cowen Health Care Conference, taking place in Boston, MA on Wednesday, March 5, 2025, at 11:50 AM ET. To listen to the live webcast of the presentation, please register . A replay of the event will also be posted to MediWound’s website on the ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.